Your Article Summary
Regulatory update for REZONIC (casopitant mesylate)
GlaxoSmithKline, 06/24/09
GlaxoSmithKline confirmed that it has received a complete response letterfrom the FDA related to the application for casopitant. The company is reviewing this letter and will engage with the FDA to determine appropriate next steps. one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09
Article Search
Sponsor


See Latest Articles


